Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation

NCT04575779 · clinicaltrials.gov ↗

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Allogenic Bone Marrow Transplantation

Interventions

DRUG: Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h

Sponsor

Shaymaa Mohammed El-Awady